P2857
Increase in pulse rate with semaglutide did not result in increased adverse cardiac events in subjects with type 2 diabetes in the SUSTAIN 6 cardiovascular outcomes trial

Extract

Background: Type 2 diabetes (T2D) and elevated blood pressure (BP) are commonly associated with each other. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) improve glucose control and produce small reductions in BP, but increase pulse rate. Beta-blockers, used to lower BP, are commonly used in patients with T2D; they reduce pulse rate. Semaglutide, a once-weekly GLP-1RA, has demonstrated robust reductions in cardiovascular (CV) events, HbA1c and body weight in SUSTAIN 6, a dedicated CV outcomes trial in subjects with T2D at high risk of CV events.

Purpose: To evaluate the effect of semaglutide on resting pulse rate in the SUSTAIN 6 trial and the effect of background beta-blocker use on pulse rate. Additionally to assess whether the increase in pulse rate with semaglutide leads to increased adverse cardiac events.

Methods: In this post hoc analysis of SUSTAIN 6, subjects were stratified by beta-blocker use at baseline and at end of trial to evaluate the effect of beta-blocker use on pulse rate.